deltatrials
Completed PHASE2 INTERVENTIONAL 9-arm NCT01518998

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

Sponsor: Asan Medical Center

Conditions Hypertension
Interventions Fimasartan , Amlodipine, Placebo
Updated 10 times since 2017 Last updated: Jun 29, 2016 Started: Aug 31, 2011 Primary completion: Oct 31, 2013 Completion: Nov 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01518998, this PHASE2 trial focuses on Hypertension and remains completed. Sponsored by Asan Medical Center, it has been updated 10 times since 2011, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshotCompleted~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshotCompleted~Jun 2018 – ~Feb 2020 · 20 months · monthly snapshotCompleted~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Present [monthly]

    Completed PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2020 — Sep 2020 [monthly]

    Completed PHASE2

  3. Jun 2018 — Feb 2020 [monthly]

    Completed PHASE2

  4. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Asan Medical Center
  • Boryung Pharmaceutical Co., Ltd
  • Busan National University Yangsan Hospital
  • Catholic University of Korea Saint Paul's Hospital
  • Cheil General Hospital and Women's Healthcare Center
  • Chonnam National University Hospital
  • Chungnam National University
  • Daegu Catholic University Medical Center
  • DongGuk University
  • Gachon University Gil Medical Center
  • Hallym University Kangnam Sacred Heart Hospital
  • Hanyang University Seoul Hospital
  • Inha University Hospital
  • Inje University
  • Jeju National University Hospital
  • Kangbuk Samsung Hospital
  • Korea University Guro Hospital
  • Kyungpook National University Hospital
  • Samsung Medical Center
  • Seoul National University Bundang Hospital
  • Seoul National University Hospital
  • Soon Chun Hyang University
  • The Catholic University of Korea
  • Wonju Severance Christian Hospital
  • Wonkwang University Hospital
  • Yeungnam University Hospital
Data source: Boryung Pharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations